By Fineline Cube Zhifei Biological (SHE: 300122) announced that it has submitted a clinical trial application in China for its nasal spray recombinant respiratory syncytial virus vaccine (chimpanzee adenovirus vector), referred to as the “nasal spray recombinant RSV vaccine.” The candidate is intended to prevent lower respiratory tract infections caused by RSV.
Regulatory Submission Overview
| Item | Detail |
|---|---|
| Sponsor | Zhifei Biological (SHE: 300122) |
| Product | Nasal spray recombinant respiratory syncytial virus vaccine (chimpanzee adenovirus vector) |
| Submission Type | Clinical trial application (China) |
| Indication | Prevention of lower respiratory tract infections caused by RSV |
| Administration Route | Nasal spray |
| Announcement Date | 10 Aug 2026 |
Disease Background – Respiratory Syncytial Virus (RSV)
- Pathogen Profile: RSV is a common respiratory pathogen
- High‑Risk Populations: One of the primary causes of lower respiratory tract infections in:
- Infants
- The elderly
- Immunocompromised individuals
- Unmet Need: RSV disease burden remains substantial across vulnerable age groups globally, driving active vaccine development worldwide.
Product Profile – Nasal Spray Recombinant RSV Vaccine
| Attribute | Detail |
|---|---|
| Modality | Recombinant vaccine |
| Vector | Chimpanzee adenovirus vector |
| Administration | Nasal spray (needle‑free) |
| Intended Use | Prevention of lower respiratory tract infections caused by RSV |
Mechanism of Action – Mucosal Immunity
By inducing mucosal immune responses in the respiratory tract via nasal spray administration, the candidate vaccine is designed to:
- Establish the first line of defense in the respiratory system — where RSV infection begins
- Simultaneously trigger both humoral and cellular immunity — a dual immune response
- Provide a more convenient method of vaccination — needle‑free nasal spray delivery may improve uptake and accessibility
Strategic Rationale & Market Impact
- Mucosal Delivery Differentiation: Unlike intramuscular RSV vaccine candidates, Zhifei’s nasal spray approach aims to induce mucosal immunity directly at the site of RSV entry — potentially offering earlier and more targeted protection against lower respiratory tract infection.
- Dual Immune Response: Triggering both humoral and cellular immunity positions the candidate as a potentially comprehensive prophylactic option, particularly for populations where cellular immunity contributes to durable protection.
- Needle‑Free Advantage: The nasal spray route removes injection‑related barriers, supporting broader vaccination uptake among infants, elderly and immunocompromised populations.
- Portfolio Expansion: The submission reinforces Zhifei Biological’s push into the fast‑growing RSV vaccine space, a market attracting major global players as the first RSV vaccines reach older adults.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical trial application’s review outcome, the candidate’s development trajectory, and commercial potential. Actual results may differ due to risks including regulatory decisions, clinical trial results, and competitive dynamics.-Fineline Info & Tech